Translation: Original published in Finnish on 8/7/2026 at 7:11 am EEST.

iCare, part of the Revenio Group, announced a strategic partnership and a minority investment in EyeCheq, a US-based eye health innovation company. This partnership aims to accelerate the adoption and accessibility of automated screening solutions in the United States, as well as advance the development of AI-based diagnostics. In connection with the investment, Revenio's Vice President of U.S. Sales, John Floyd, was appointed to EyeCheq's board of directors.

EyeCheq stations are designed for easily accessible environments, such as retail labs and pharmacies, occupational health clinics, and primary healthcare. The stations integrate the iCare DRSplus fundus imaging device, as well as other ophthalmic devices, and imaging results are reviewed by EyeCheq’s network of licensed eye care physicians (optometrists and ophthalmologists). Screening participants receive a personalized report within 24 hours, covering diabetic retinopathy, glaucoma, age-related macular degeneration, and other conditions. According to the company, pilot deployments of the stations are already underway in the US with several partners.

We view this arrangement as a strategically logical but financially minor step. As we understand it, EyeCheq is still in a very early stage of development. However, the partnership expands iCare’s distribution channels into non-traditional environments with a scalable screening concept and, in our view, could strengthen the company’s position in the growing US vision screening and eye care market. The size of the minority investment or the financial terms of the partnership were not disclosed, and the release has no impact on our estimates or stance. In the big picture, we believe the news supports Revenio's strategy of expanding beyond being solely a device manufacturer to become a more comprehensive eye care solution provider.